Literature DB >> 10086737

Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome.

E Callet-Bauchu1, G Salles, S Gazzo, C Poncet, D Morel, J Pagès, B Coiffier, P Coeur, P Felman.   

Abstract

Unbalanced translocations involving chromosome arm 17p, where the TP53 tumor suppressor gene localizes, are rarely described in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), but recent use of molecular cytogenetic techniques have indicated a significant incidence of TP53 deletions, suggesting the involvement of chromosome 17p in these disorders. By conventional karyotype, we have identified unbalanced translocations involving 17p in 14 out of 123 (11%) CLL/SLL patients with clonal abnormalities. Cases were characterized by resistance to chemotherapy and a poor clinical outcome. The karyotypes presented a high incidence of complex rearrangements and 17p translocations were characterized by various partners. In 10 cases a centric fusion was assessed by fluorescent in situ hybridization (FISH) experiments using specific centromeric probes. The incidence of dicentric translocations in these series is therefore significantly higher than usually described, arising in up to 71% (10 out of 14 cases). In all cases, translocations led to a monosomy 17p and to a TP53 monoallelic deletion. The adverse clinical outcome confirms that structural abnormalities involving chromosome 17p are associated with disease progression in patients with chronic lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086737     DOI: 10.1038/sj.leu.2401272

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.

Authors:  Lucile Baseggio; Alexandra Traverse-Glehen; Florence Petinataud; Evelyne Callet-Bauchu; Françoise Berger; Martine Ffrench; Chantal Marie Couris; Catherine Thieblemont; Dominique Morel; Bertrand Coiffier; Gilles Salles; Pascale Felman
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

2.  Jumping translocations, a novel finding in chronic lymphocytic leukaemia.

Authors:  Cecelia R Miller; Deborah Stephens; Amy S Ruppert; Frederick Racke; Andrew McFaddin; Heather Breidenbach; Huey-Jen Lin; Kathy Waller; Tammy Bannerman; Jeffrey A Jones; Jennifer A Woyach; Leslie A Andritsos; Kami Maddocks; Weiqiang Zhao; Gerard Lozanski; Joseph M Flynn; Michael Grever; John C Byrd; Nyla A Heerema
Journal:  Br J Haematol       Date:  2015-04-19       Impact factor: 6.998

3.  Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.

Authors:  Jennifer A Woyach; Nyla A Heerema; John Zhao; Andrew McFaddin; Amy Stark; Thomas S Lin; Leslie A Andritsos; Kristie A Blum; Joseph M Flynn; Jeffrey A Jones; John C Byrd
Journal:  Br J Haematol       Date:  2009-12-16       Impact factor: 6.998

4.  Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies.

Authors:  Jason A Powell; Stuart M Pitson; Alexander C Lewis; Craig T Wallington-Beddoe
Journal:  Cell Death Discov       Date:  2018-06-28

5.  Telomere and Centromere Staining Followed by M-FISH Improves Diagnosis of Chromosomal Instability and Its Clinical Utility.

Authors:  Radhia M'kacher; Bruno Colicchio; Claire Borie; Steffen Junker; Valentine Marquet; Leonhard Heidingsfelder; Kevin Soehnlen; Wala Najar; William M Hempel; Noufissa Oudrhiri; Nadège Wilhelm-Murer; Marguerite Miguet; Micheline Arnoux; Catherine Ferrapie; Wendy Kerbrat; Andreas Plesch; Alain Dieterlen; Theodore Girinsky; Philippe Voisin; Georges Deschenes; Anne-Claude Tabet; Catherine Yardin; Annelise Bennaceur-Griscelli; Michael Fenech; Patrice Carde; Eric Jeandidier
Journal:  Genes (Basel)       Date:  2020-04-27       Impact factor: 4.096

6.  The role of dicentric chromosome formation and secondary centromere deletion in the evolution of myeloid malignancy.

Authors:  Ruth N Mackinnon; Lynda J Campbell
Journal:  Genet Res Int       Date:  2011-09-27

Review 7.  The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.

Authors:  Bernard Friedenson
Journal:  BMC Cancer       Date:  2007-08-06       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.